deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06184750

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Refining Tamoxifen Dose for Premenopausal Breast Cancer Risk Reduction (RENAISSANCE): A Phase II Single Arm Trial

Sponsor: National Cancer Institute (NCI)

Conditions Breast Atypical Ductal Hyperplasia Breast Atypical Lobular Hyperplasia Breast Carcinoma Breast Ductal Carcinoma In Situ Breast Lobular Carcinoma In Situ Estrogen Receptor-Positive Breast Carcinoma
Interventions Biopsy Procedure Biospecimen Collection Mammography Questionnaire Administration Tamoxifen
Updated 20 times since 2024 Last updated: Mar 12, 2026 Started: Sep 27, 2024 Primary completion: Mar 31, 2028 Completion: Sep 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Breast Atypical Ductal Hyperplasia and Breast Atypical Lobular Hyperplasia, this trial is actively recruiting participants. The trial is conducted by National Cancer Institute (NCI) and has accumulated 20 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Dec 2024 · 2 months · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Jun 2025 · 31 days · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Jan 2026 · 3 months · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – present · 5 months · monthly snapshot

Change History

20 versions recorded

  1. Mar 2026 — Present [monthly]

    Recruiting PHASE2

  2. Feb 2026 — Mar 2026 [monthly]

    Recruiting PHASE2

  3. Jan 2026 — Feb 2026 [monthly]

    Recruiting PHASE2

  4. Oct 2025 — Jan 2026 [monthly]

    Recruiting PHASE2

  5. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE2

▶ Show 15 earlier versions

  1. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

  2. Jul 2025 — Aug 2025 [monthly]

    Recruiting PHASE2

  3. Jun 2025 — Jul 2025 [monthly]

    Recruiting PHASE2

  4. May 2025 — Jun 2025 [monthly]

    Recruiting PHASE2

  5. Apr 2025 — May 2025 [monthly]

    Recruiting PHASE2

  6. Mar 2025 — Apr 2025 [monthly]

    Recruiting PHASE2

  7. Feb 2025 — Mar 2025 [monthly]

    Recruiting PHASE2

  8. Jan 2025 — Feb 2025 [monthly]

    Recruiting PHASE2

  9. Dec 2024 — Jan 2025 [monthly]

    Recruiting PHASE2

  10. Oct 2024 — Dec 2024 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Sep 2024 — Oct 2024 [monthly]

    Not Yet Recruiting PHASE2

  12. Jul 2024 — Sep 2024 [monthly]

    Not Yet Recruiting PHASE2

  13. Mar 2024 — Jul 2024 [monthly]

    Not Yet Recruiting PHASE2

  14. Feb 2024 — Mar 2024 [monthly]

    Not Yet Recruiting PHASE2

  15. Jan 2024 — Feb 2024 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations